Mind Medicine Inc (MNMD)

Apr 16, 2025

Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com

Apr 16, 2025

Apr 16, 2025

MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks

Apr 16, 2025

Apr 16, 2025

Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India

Apr 16, 2025

Apr 15, 2025

MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria

Apr 15, 2025

Apr 15, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus

Apr 15, 2025

Apr 15, 2025

MindMed launches phase 3 LSD study for depression - Investing.com Australia

Apr 15, 2025

Apr 15, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus

Apr 15, 2025

Apr 15, 2025

Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Breakthrough: First-Ever Phase 3 LSD Depression Trial Begins at MindMed - Stock Titan

Apr 15, 2025

Apr 07, 2025

MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener

Apr 07, 2025

Apr 04, 2025

MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India

Apr 04, 2025

Apr 04, 2025

Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com

Apr 04, 2025

Apr 04, 2025

MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Mar 30, 2025

MNMD Stock Forecast From 2025 To 2040 - Exla Resources

Mar 30, 2025

Mar 26, 2025

Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 26, 2025

MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks

Mar 26, 2025

Mar 26, 2025

Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com India

Mar 26, 2025

Mar 24, 2025

MindMed Announces New Employee Inducement Grants - Business Wire

Mar 24, 2025

Mar 24, 2025

MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR

Mar 21, 2025

Mar 17, 2025

MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 17, 2025

MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow

Mar 17, 2025

Mar 17, 2025

MindMed appoints new Chief Commercial Officer - Investing.com

Mar 17, 2025

Mar 17, 2025

MindMed Taps Former Jazz Pharma Executive to Lead MM120 Anxiety Drug Launch - Stock Titan

Mar 17, 2025

Mar 12, 2025

MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com

Mar 12, 2025

Mar 11, 2025

MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India

Mar 11, 2025

Mar 10, 2025

What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World

Mar 10, 2025

Mar 10, 2025

Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World

Mar 10, 2025

Mar 10, 2025

Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025

Mar 08, 2025

Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider

Mar 08, 2025

Mar 08, 2025

Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mar 08, 2025

Mar 08, 2025

Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mar 08, 2025

Mar 07, 2025

Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mar 07, 2025

Mar 07, 2025

H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India

Mar 07, 2025

Mar 07, 2025

Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks

Mar 07, 2025

Mar 07, 2025

Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strat - GuruFocus

Mar 07, 2025

Mar 07, 2025

Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Mar 07, 2025

Mar 06, 2025

MindMed Advances Clinical Trials and Strengthens Financial Position - TipRanks

Mar 06, 2025

Mar 06, 2025

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months - MSN

Mar 06, 2025

Mar 06, 2025

MindMed posts strong cash position, progress on LSD treatment - Green Market Report

Mar 06, 2025

Mar 06, 2025

Earnings call transcript: MindMed misses Q4 2024 EPS forecast, stock slides - Investing.com

Mar 06, 2025

Mar 06, 2025

Mind Medicine (MindMed) Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

Mar 06, 2025

Mind Medicine (MindMed) Inc. SEC 10-K Report - TradingView

Mar 06, 2025

Mar 06, 2025

Mind Medicine reports Q4 EPS (41c), consensus (28c) - TipRanks

Mar 06, 2025

Mar 06, 2025

MIND MEDICINE Earnings Results: $MNMD Reports Quarterly Earnings - Nasdaq

Mar 06, 2025

Mar 06, 2025

Mind Medicine (MindMed) Inc. Loss At -$34.74 Mln In Q4 - Nasdaq

Mar 06, 2025

Mar 06, 2025

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates - Joplin Globe

Mar 06, 2025

Mar 04, 2025

MindMed to Present at Leerink’s Global Healthcare Conference 2025 - TipRanks

Mar 04, 2025

Mar 04, 2025

Can MindMed's Conference Appearance Signal New Brain Health Breakthroughs? - Stock Titan

Mar 04, 2025

Mar 03, 2025

Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily

Mar 03, 2025